Literature DB >> 3617501

Quantitative relationships between an influenza virus and neutralizing antibody.

H P Taylor, S J Armstrong, N J Dimmock.   

Abstract

In this quantitative study of the interaction of influenza virus with neutralizing antibody we have determined the maximum number of antibody molecules which can bind to the haemagglutinin (HA) of native influenza A/FPV/Rostock/34 (H7N1) particles in aqueous suspension and the minimum number which is required to cause neutralization. Using radiolabelled immunoglobulins approximately one IgG molecule, whether of monoclonal or polyclonal origin, binds per HA spike under conditions of antibody saturation. In the same manner, we have determined that when infectivity is neutralized by 63% (1/e) about 70 molecules of monoclonal IgGs HC2 and HC10 were bound per virus particle and this is supported by independent evidence from electron microscopy. However, the kinetics of neutralization were single-hit or at most, under critical conditions of low temperature (4 degrees) and minimal neutralizing concentrations of antibody, two-hit. This apparent conflict is reconciled by a hypothesis which proposes that neutralization occurs only when antibody binds to certain "neutralization relevant" HA spikes which are in the minority. It is suggested that these only differ from the majority of "neutralization irrelevant" HA spikes by their transmembrane interaction with the core of the virion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3617501     DOI: 10.1016/0042-6822(87)90466-1

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  36 in total

1.  Stalk model of membrane fusion: solution of energy crisis.

Authors:  Yonathan Kozlovsky; Michael M Kozlov
Journal:  Biophys J       Date:  2002-02       Impact factor: 4.033

2.  Reversible stages of the low-pH-triggered conformational change in influenza virus hemagglutinin.

Authors:  Eugenia Leikina; Corinne Ramos; Ingrid Markovic; Joshua Zimmerberg; Leonid V Chernomordik
Journal:  EMBO J       Date:  2002-11-01       Impact factor: 11.598

3.  Regulation of virus neutralization and the persistent fraction by TRIM21.

Authors:  W A McEwan; F Hauler; C R Williams; S R Bidgood; D L Mallery; R A Crowther; L C James
Journal:  J Virol       Date:  2012-05-30       Impact factor: 5.103

Review 4.  Insights into neutralization of animal viruses gained from study of influenza virus.

Authors:  M C Outlaw; N J Dimmock
Journal:  Epidemiol Infect       Date:  1991-04       Impact factor: 2.451

5.  Three antibody molecules can bind simultaneously to each monomer of the tetramer of influenza virus neuraminidase and the trimer of influenza virus hemagglutinin.

Authors:  D C Jackson; B S Crabb; P Poumbourios; W R Tulip; W G Laver
Journal:  Arch Virol       Date:  1991       Impact factor: 2.574

6.  Differential neutralization efficiency of hemagglutinin epitopes, antibody interference, and the design of influenza vaccines.

Authors:  Wilfred Ndifon; Ned S Wingreen; Simon A Levin
Journal:  Proc Natl Acad Sci U S A       Date:  2009-05-13       Impact factor: 11.205

7.  Masking of antigenic epitopes by antibodies shapes the humoral immune response to influenza.

Authors:  Veronika I Zarnitsyna; Ali H Ellebedy; Carl Davis; Joshy Jacob; Rafi Ahmed; Rustom Antia
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2015-09-05       Impact factor: 6.237

Review 8.  Deconstructing the Antiviral Neutralizing-Antibody Response: Implications for Vaccine Development and Immunity.

Authors:  Laura A VanBlargan; Leslie Goo; Theodore C Pierson
Journal:  Microbiol Mol Biol Rev       Date:  2016-10-26       Impact factor: 11.056

9.  A mechanism of protein-mediated fusion: coupling between refolding of the influenza hemagglutinin and lipid rearrangements.

Authors:  M M Kozlov; L V Chernomordik
Journal:  Biophys J       Date:  1998-09       Impact factor: 4.033

10.  Quantitative model of antibody- and soluble CD4-mediated neutralization of primary isolates and T-cell line-adapted strains of human immunodeficiency virus type 1.

Authors:  P J Klasse; J P Moore
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.